Triamcinolone acetonide - Generic Drug Details

What are the generic drug sources for triamcinolone acetonide and what is the scope of freedom to operate?

Triamcinolone acetonide is the generic ingredient in twenty-seven branded drugs marketed by Abbvie, Chattem Sanofi, Astellas, Ivax Pharms, Delcor Asset Corp, Teva, Solvay, Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Chartwell Rx, Cosette, Encube, Fougera Pharms, Glenmark Pharms Ltd, Macleods Pharms Ltd, Micro Labs, Morton Grove, Norvium Bioscience, Padagis Us, Pharmaderm, Pharmafair, Strides Pharma, Taro, Topiderm, Crown Labs, Savage Labs, Pacira Pharms Inc, Apothecon, Amneal, Eugia Pharma, Long Grove Pharms, Mylan Labs Ltd, Parnell, Sandoz, Teva Pharms Usa, Watson Labs, Allergan, Harrow Eye, Epic Pharma Llc, Pai Holdings Pharm, Quagen, Wockhardt Bio Ag, Aurobindo Pharma Ltd, Cintex Svcs, Glenmark Speclt, Padagis Israel, Rising, Cmp Pharma Inc, Sciegen Pharms Inc, Lupin Atlantis, Sanofi Aventis Us, Apotex, Perrigo Pharma Intl, Sun Pharm Inds Inc, and Bausch And Lomb Inc, and is included in one hundred and thirty-nine NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Triamcinolone acetonide has one hundred and fifty-seven patent family members in twenty-nine countries.

There are twenty-six drug master file entries for triamcinolone acetonide. Seventy-three suppliers are listed for this compound.

Summary for triamcinolone acetonide

International Patents:	157
US Patents:	7
Tradenames:	27
Applicants:	57
NDAs:	139
Drug Master File Entries:	26
Finished Product Suppliers / Packagers:	73
Raw Ingredient (Bulk) Api Vendors:	80
Clinical Trials:	262
Patent Applications:	6,970
Drug Prices:	Drug price trends for triamcinolone acetonide
Drug Sales Revenues:	Drug sales revenues for triamcinolone acetonide
What excipients (inactive ingredients) are in triamcinolone acetonide?	triamcinolone acetonide excipients list
DailyMed Link:	triamcinolone acetonide at DailyMed

See drug prices for triamcinolone acetonide

See drug sales revenues for triamcinolone acetonide

Recent Clinical Trials for triamcinolone acetonide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ain Shams University	Phase 3
CHU de Reims	N/A
Tanta University	N/A

See all triamcinolone acetonide clinical trials

Pharmacology for triamcinolone acetonide

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Medical Subject Heading (MeSH) Categories for triamcinolone acetonide

Anti-Inflammatory Agents

Glucocorticoids

Immunosuppressive Agents

Anatomical Therapeutic Chemical (ATC) Classes for triamcinolone acetonide

A01AC	Corticosteroids for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

C05AA	Corticosteroids
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D07AB	Corticosteroids, moderately potent (group II)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07XB	Corticosteroids, moderately potent, other combinations
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for triamcinolone acetonide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fougera Pharms	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	CREAM;TOPICAL	085692-003	Approved Prior to Jan 1, 1982	AT	RX	Yes	Yes
Delcor Asset Corp	KENALOG	triamcinolone acetonide	LOTION;TOPICAL	084343-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Morton Grove	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	CREAM;TOPICAL	088094-001	Sep 1, 1983		DISCN	No	No
Morton Grove	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	OINTMENT;TOPICAL	088090-001	Sep 1, 1983		DISCN	No	No
Ivax Pharms	FLUTEX	triamcinolone acetonide	CREAM;TOPICAL	085539-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for triamcinolone acetonide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	AZMACORT	triamcinolone acetonide	AEROSOL, METERED;INHALATION	018117-001	Apr 23, 1982
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013
Harrow Eye	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013

International Patents for triamcinolone acetonide

Country	Patent Number	Title	Estimated Expiration
Eurasian Patent Organization	032039	УСТРОЙСТВО ДЛЯ ПРОВЕДЕНИЯ ГЛАЗНОЙ ИНЪЕКЦИИ (APPARATUS FOR OCULAR INJECTION)
South Africa	201208069	METHODS AND DEVICES FOR DRUG DELIVERY TO OCULAR TISSUE USING MICRONEEDLE
Russian Federation	2018100114	КОРТИКОСТЕРОИДЫ ДЛЯ ЛЕЧЕНИЯ СУСТАВНОЙ БОЛИ
Denmark	2262506
Ukraine	111162	ІН'ЄКЦІЙНА КОМПОЗИЦІЯ АЦЕТОНІДУ ТРИАМЦИНОЛОНУ ДЛЯ ЛІКУВАННЯ БОЛЮ

Triamcinolone acetonide Market Analysis and Financial Projection Experimental

Triamcinolone Acetonide Market Dynamics and Financial Trajectory

Market Introduction and Definition

Triamcinolone acetonide, a potent corticosteroid, is widely used to manage and alleviate the symptoms of various chronic inflammatory diseases. The global market for triamcinolone acetonide is driven by several key factors, including the increasing prevalence of chronic diseases, the rise in the geriatric population, and advancements in healthcare infrastructure.

Market Size and Growth Projections

The global triamcinolone market was valued at $0.9 billion in 2023 and is projected to reach $1.3 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 3.8% from 2024 to 2033[1][5].

Key Drivers of Market Growth

Increasing Prevalence of Chronic Diseases

The rise in chronic inflammatory diseases such as asthma, arthritis, allergies, and various dermatological conditions is a significant driver of the triamcinolone market. These conditions are becoming more common due to factors like aging populations, unhealthy lifestyles, and environmental changes. Triamcinolone, with its potent anti-inflammatory and immunosuppressive properties, is frequently prescribed to treat these chronic diseases, thereby driving market growth[1][5].

Rise in Geriatric Population

The global population is aging, leading to an increase in age-related chronic and inflammatory diseases. Elderly individuals are more prone to conditions like arthritis, asthma, and dermatological disorders due to the natural decline in immune function and the cumulative wear and tear on the body’s systems over time. This demographic shift is expected to significantly contribute to the growth of the triamcinolone market[1].

Expansion of Healthcare Infrastructure

Advanced healthcare systems, particularly in regions like North America and Europe, play a crucial role in the market growth. Significant investments in research and development, along with improving medical infrastructure in the Asia-Pacific region, are also driving the demand for triamcinolone[1][5].

Regional Outlook

North America

North America, particularly the United States, dominates the triamcinolone market due to the high prevalence of chronic diseases, advanced healthcare systems, and significant investment in research and development. The widespread availability of triamcinolone in various forms contributes to its strong market presence in this region[1][5].

Europe

Europe also exhibits substantial market growth, driven by a well-established healthcare system and an increasing incidence of autoimmune and inflammatory diseases. Countries like Germany, France, and the UK are key markets within Europe, benefiting from high levels of healthcare access and a growing aging population[5].

Asia-Pacific

The Asia-Pacific region is experiencing rapid expansion in the triamcinolone market. This growth is fueled by increasing healthcare awareness, rising prevalence of chronic conditions, and improving healthcare infrastructure in countries like China, India, and Japan. The large population base and growing middle class in these countries also drive demand for effective and accessible healthcare solutions[1][5].

Distribution Channels

The drug store segment is expected to register the fastest growth during the forecast period. Drug stores are highly accessible to the general population, providing a convenient and immediate point of purchase for triamcinolone products. Hospitals and online pharmacies also play significant roles in the distribution of triamcinolone, but drug stores dominate the market share[5].

Key Market Players

Several pharmaceutical companies are key players in the triamcinolone market, including:

• Novartis AG
• Mylan N.V.
• Lupin
• Teva Pharmaceuticals
• Akorn Inc
• Cosette Pharmaceuticals, Inc
• Bristol Myers Squibb Company
• Glenmark Pharmaceuticals
• Taro Pharmaceutical Industries
• Sun Pharmaceutical Industries Limited[1][3].

Financial Trajectory

Revenue Growth

The global triamcinolone market is expected to grow steadily, driven by the increasing demand for effective treatments for chronic inflammatory diseases. The market size is projected to increase from $0.9 billion in 2023 to $1.3 billion by 2033, with a CAGR of 3.8% during the forecast period[1][5].

Regional Revenue Contribution

North America, particularly the U.S., contributes significantly to the revenue due to its large patient population and advanced healthcare infrastructure. The Asia-Pacific region is also expected to contribute substantially to the revenue growth, driven by its large population base and improving healthcare infrastructure[1][5].

Prescription Data and Usage

Triamcinolone is widely used in various forms, including creams, injections, and inhalers, to treat a range of conditions such as eczema, dermatitis, allergies, psoriasis, and others. The chronic nature of these conditions often requires long-term management, leading to sustained and repeat use of triamcinolone products. For instance, the prevalence of allergic diseases in the elderly is estimated to be around 5-10%, further driving the demand for triamcinolone[1].

Market Opportunities and Challenges

Opportunities

• Increasing Healthcare Expenditure: Rising healthcare expenditure, especially in countries like China, Japan, and India, is expected to fuel market growth.
• Advancements in Healthcare Infrastructure: Improving medical infrastructure and increasing awareness about chronic diseases and their treatments are significant opportunities for market expansion[1][5].

Challenges

• Regulatory Environment: Changes in regulatory policies, such as the implementation of the 340B Drug Pricing Program, can impact the pricing and profitability of triamcinolone products.
• Competition: The market is competitive, with several key players, which can lead to pricing pressures and market share competition[2].

Illustrative Statistics

• Market Size: The global triamcinolone market was valued at $0.9 billion in 2023 and is projected to reach $1.3 billion by 2033[1][5].
• CAGR: The market is expected to grow at a CAGR of 3.8% from 2024 to 2033[1][5].
• Prevalence of Chronic Diseases: The prevalence of allergic diseases in the elderly is estimated to be around 5-10%[1].

Quotes from Industry Experts

"The rise in geriatric population is expected to significantly contribute to the growth of the triamcinolone market... Elderly individuals are more prone to these ailments due to the natural decline in immune function and the cumulative wear and tear on the body’s systems over time."[1]

Highlight

"The global triamcinolone market was valued at $0.9 billion in 2023 and is projected to reach $1.3 billion by 2033, growing at a CAGR of 3.8% from 2024 to 2033." - Allied Market Research[1].

Key Takeaways

• The global triamcinolone market is driven by the increasing prevalence of chronic inflammatory diseases and the rise in the geriatric population.
• North America, particularly the U.S., dominates the market due to its advanced healthcare infrastructure and high prevalence of chronic diseases.
• The Asia-Pacific region is experiencing rapid growth due to improving healthcare infrastructure and increasing awareness about chronic diseases.
• The market is expected to grow at a CAGR of 3.8% from 2024 to 2033, reaching $1.3 billion by 2033.
• Key players include Novartis AG, Mylan N.V., Lupin, and Bristol Myers Squibb Company, among others.

FAQs

Q: What is the projected market size of triamcinolone by 2033? A: The global triamcinolone market is projected to reach $1.3 billion by 2033[1][5].

Q: What is the CAGR of the triamcinolone market from 2024 to 2033? A: The market is expected to grow at a CAGR of 3.8% from 2024 to 2033[1][5].

Q: Which region dominates the triamcinolone market? A: North America, particularly the United States, dominates the triamcinolone market[1][5].

Q: What are the main drivers of the triamcinolone market growth? A: The main drivers include the increasing prevalence of chronic inflammatory diseases and the rise in the geriatric population[1].

Q: Who are the key players in the triamcinolone market? A: Key players include Novartis AG, Mylan N.V., Lupin, Teva Pharmaceuticals, and Bristol Myers Squibb Company, among others[1][3].

Sources

1. Allied Market Research - Triamcinolone Market Statistics, Trends | Forecast - 2033
2. Stock Titan - Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
3. Valuates Reports - Triamcinolone Acetonide Injection - Market Size
4. Pacira BioSciences - Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022
5. Globe Newswire - Triamcinolone Market to Reach $1.3 Billion, Globally, by 2033 at 3.8% CAGR - Allied Market Research